Thymocytes from DO1 T-cell-receptor trasgenic mice undergo apoptosis, or programmed cell death, when chicken ovalbumin-(323-339) 
thymocyte clonal deletion entirely depends on the stage at which the thymocytes are vulnerable to the onset of apoptosis, rather than on the nature of the peptide antigen-presenting cells. Furthermore, thymic nurse cell line TNC-R3.1 could cause deletion, strongly suggesting that some thymic epithelial/stromal components are potentially capable of participating in negative selection. In all cases examined, little deletion could be induqed at a peptide concentration <10 nM, thus defining the minimum amount of peptid& antigen required for negative selection. The peptide-dependent in vitro negative-selection system will allow further dissection of the molecular and cllular processes involved in clonal deletion due to apoptosis in the thymus.
Clonal deletion or negative selection of self-reactive T cells during thymic development plays a critical role in inducing immunological self-tolerance (1) (2) (3) . With transgenic mice bearing T-cell receptor (TCR) of defined peptide antigen specificity, self-reactive T cells have been shown to undergo apoptosis, or programmed cell death, during the process of clonal deletion in the thymus (4) . Thymocytes can thus be triggered to undergo apoptosis upon engagement of the TCR with the peptides presented in the context of the appropriate major histocompatibility complex (MHC) molecules. The exact nature of the cell-cell interactions or the signaling pat ways that precipitate programmed cell death in the developing thymocytes is unknown (5) (6) (7) (8) (9) . Tolerance induction is thought to largely depend on the antigen-presenting capability of the bone-marrow-derived cells like macrophages and dendritic cells, whereas the role of thymic epitheligl/stromal cells is controversial (10) (11) (12) . However, little is known about the amount and form of antigen required to delete the developing thymocytes. We have recently developed a TCR transgenic mouse, DO10, that has a TCR that recognizes a chicken ovalbumin (cOVA) peptide-(323-339) in the context of a class II MHC molecule, I-Ad (4) . When cOVA-(323-339) was injected i.p. into these mice, the developing, immature thymocytes underwent apoptosis in an antigen-specific manner. Using these mice, we now report on the development of a simple in vitro thymocyte clonaldeletion system that can be used to elucidate the cellular and peptide-antigen requirements for inducing clonal deletion.
EXPERIMENTAL PROCEDURES
Mice. TCR transgenic mice (DO10) bearing TCR from a hybridoma, DO11.10, with specificity for cOVA-(323-339) and I-Ad have been backcrossed to BALB/c mice and are maintained in our own animal facility. KA mice were created by the microinjection of I-Ad genes (a and f3) driven by class I MHC Kb promoter into mouse embryos and maintained in the H-2d background (13) .
Cells. RT2.3.3.HD6, I-Ad-transfected L-cell fibroblasts, was provided by R. Germain (National Institutes of Health, Bethesda, MD) (14) . TNC-R3.1, a thymic nurse cell line from a AKR/J (H-2k) mouse that shows properties similar to thymic nurse cells, was transfected with genomic I-Ad genes (a and is) linked to class I MHC Kb promoter and selected for their cell-surface expression (15) . A20 and TA3, B-cell lymphoma lines, were obtained from E. Unanue and T. Braciale (Washington University, St. Louis).
Peptides. Peptides were made by using a model 430 peptide synthesizer (Applied Biosystems) and purified by HPLC as described (16) . Peptide sequences are as follows: cOVA-(323-339), ISQAVHAAHAEINEAGR, and cOVA-(324-334), SQAVTAAHAEI (which also has a histidine to threonine change at position 328).
Flow Cytometry. Lyt-2 fluorescein isothiocyanate (Becton Dickinson), L3T4-phycoerythrin (Becton Dickinson), and biotinylated KJ1-26 (anticlonotypic TCR monoclonal antibody) plus streptavidin-Red613 (GIBCO/BRL) were used. Three-color flow cytometric analysis was done with FACScan (Becton Dickinson). Dead cells were gated out by staining with propidium iodide at 5 Ag/ml (Sigma) 
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Detection of DNA Fragmentation and EM. Thymocytes and A20 cells were cultured as described, with cOVA-(324-334) or cOVA-(323-339) at 1 ttM. Cells were harvested after 5 hr because DNA fragmentation can be seen earlier than the decrease of the CD4+CD8+ population. Fragmented DNA was prepared from 5 x 105 thymocytes by the method of Newell et al. (17) . Samples were separated by electrophoresis on a 1.5% agarose gel containing ethidium bromide at 0.5 Ag/ml. For EM, thymocytes and A20 cells were cultured, as described, with cOVA-(324-334) or cOVA-(323-339) at 1 ;M for 20 hr. Culture medium was aspirated and immediately replaced by an isotonic 3% (wt/vol) glutaraldehyde solution. Electron micrographs were taken as described (4) .
RESULTS AND DISCUSSION cOVA-(323-339) Deletes TCR+CD4+CD8+ Immature Thymocytes in Vitro. T cells from the DO10 TCR transgenic mice respond to cOVA-(323-339) when presented in the context of I-Ad and bear the TCR clonotypic marker recognized by the monoclonal antibody KJ1-26 (18, 19) . Upon in vivo administration of cOVA-(323-339), KJ1-26+ CD4+CD8+ doublepositive (DP) immature thymocytes are preferentially deleted. Because cOVA-(324-334), which binds to I-Ad but cannot stimulate the transgenic TCR, does not cause deletion, apoptosis among the DP thymocytes requires the recognition ofboth the I-Ad and cOVA-(323-339) by the KJ1-26+ TCR (4, 20, 21) . Previous in vivo studies showed that apopProc. Natl. Acad. Sci. USA 89 (1992) 9001 totic cells were distributed extensively and uniformly throughout the thymic cortex (4 preferentially.) Furthermore, the appropriate I-Ad+ fibroblasts were necessary for deletion to occur (Fig. 1C) deletion of the immature KJ1-26+ DP thymocytes (4) . To determine the peptide concentration required to induce apoptosis in vitro, dose-response curves were determined with RT2.3.3.HD6, T-cell-depleted splenocytes, and B-cell lymphoma line A20 as APCs. When thymocytes were cultured with RT2.3.3.HD6 or splenic APCs, %50%o of the DP cells were deleted at several hundred nanomolar range (Fig. 3) . No effect of peptide was seen at <10 nM, thus setting the lower limit of peptide concentration necessary to precipitate clonal deletion by these APCs. In contrast, 10 nM of cOVA-(323-339) was clearly sufficient to cause deletion with A20 cells (Fig. 3) . However, once peptide concentration was lowered to 1 nM, even A20 cells could not elicit clonal deletion. Although the immature DP cells were deleted, the number of singlepositive cells showed little change with RT2.3.3.HD6 (Fig. 3) or with other APCs (data not shown). Rather, single-positive cells appeared to be activated under these conditions by blastogenesis (Fig. 4) and [3H]thymidine-uptake assays (31) .
To see whether thymocytes themselves can present and mediate apoptosis, we crossed the DO10 mice to KA mice. In the KA mice, the transgenic I-Ad is expressed on thymocytes because the I-Ad genes are transcribed by MHC class I Kb promoter (13) . In F1 (DO10 x KA) mice, we found an increased percentage of KJ1-26+CD4+CD8-cells, probably due to the distinctive expression pattern ofthe I-Ad transgene ( Fig. 5 and unpublished data) . Although in F1 mice (DO10 x KA), the percentage of DP cells is lower than in DO10 mice, almost complete deletion ofthese DP cells was seen with A20 cells and cOVA-(323-339). Furthermore, a similar extent of deletion was seen when A20 cells were absent (Fig. 5) . These results imply that T cells themselves can mediate apoptosis, characterized by DNA antigens that can interact with the specific TCRs are present on the T-cell surfaces (data not shown).
Although specific comparisons of the differential effectiveness as inducers of clonal deletion cannot be fully ascertained due to many potential differences-such as cell size, expression level of I-Ad, nature of the various adhesion molecules among others-B cells were consistently more effective than other APCs. A similar instance of the B cells being more effective than L-cells has been recently described by using T-cell activation as an assay (21) . We suggest, then, that a peptide concentration of at least 10 nM is required in the thymus before an individual can be tolerized against such antigens by clonal deletion. Thus, for immunological tolerance to develop against antigens that may be found extrathymically or circulating in the serum, free peptides must be available at >10 nM threshold (22) . Alternatively, specialized APCs may exist in the thymus that can function to specifically focus proteins and peptide antigens, leading to clonal deletion of the self-reactive thymocytes despite lower nominal concentrations in vivo.
TNC-R3.1, a Thymic Nurse Cell Line, Can Also Present Peptides and Mediate Clonal Deletion in Vitro. In contrast to the general agreement that the radio-resistant portion of the thymus is crucial in mediating positive selection that results in MHC restriction, the role of thymocytes in inducing tolerance has been controversial (10) (24) (25) (26) (27) (28) . As shown (4) (29) . By contrast, -70% ofV311 + T cells was depleted under a very stringent system in which host-type bone-marrow-derived cells were thoroughly removed (10) . One obvious difference between these systems and the one we report here is that these studies rely on the analysis of heterogeneous populations of T cells with potentially various TCR affinities. It is also possible that the deletion efficiency mediated by the superantigens differs, at least in a quantitative manner, from conventional peptide antigens (for review, see ref. 30 ). However, most importantly, the differential distribution of the available peptide antigens (or superantigens) probably determines which cells can delete the individual thymocytes. Because our in vitro model system relies on peptide-induced apoptosis, we have effectively bypassed the influence of differential access to the protein antigens or subsequent antigen-processing capabilities of individual non-T and T cells that may be present in the thymus. Thus, in vivo, the capacity of individual cell types to mediate thymocyte deletion may depend heavily on (i) the capability of the cells to have access to protein antigens from both exogenous and endogenous sources and (ii) the capability of the cells to process them effectively for presentation. Our data suggest that once the peptide antigen has been made available on the cell surface, most cells can induce clonal deletion of the immature thymocytes. The in vitro system described here should help in further defining the cellular and molecular events that accompany the onset of apoptosis in immature thymocytes, leading to clonal deletion of selfreactive T cells.
